Skip to content

Interim report January – September 2024: 12% CURRENCY-NEUTRAL INCREASE IN SALES

THIRD QUARTER 2024 (JUL – SEP)

Net sales amounted to SEK 231.8 (210.2) million, an increase of 10 percent compared with the corresponding period in the preceding year.

License revenue amounted to SEK 65.0 (55.5) million and accounted for 28 (26) percent of net sales.

The gross margin was 69 (69) percent.

Operating profit amounted to SEK 45.8 (50.7) million.

Net profit amounted to SEK 43.0 (47.4) million, corresponding to earnings per share of SEK 0.84 (0.93).

Cash flow from operating activities amounted to SEK 22.1 (53.1) million. As at September 30, 2024, cash and cash equivalents amounted to SEK 666.3 (606.1) million.

FIRST NINE MONTHS OF 2024 (JAN – SEP)

Net sales amounted to SEK 632.5 (655.6) million, a decrease of 4 percent compared with the preceding year.

License revenue amounted to SEK 195.3 (201.8) million and accounted for 31 (31) percent of net sales.

The gross margin was 68 (69) percent.

Operating profit amounted to SEK 105.2 (151.5) million.

Net profit amounted to SEK 95.4 (136.0) million, corresponding to earnings per share of SEK 1.87 (2.67).

Cash flow from operating activities amounted to SEK 80.6 (198.7) million.

Gothenburg, Sweden, November 14, 2024
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

Skip to navigation